HoldsUp

Charles Raison

University of Wisconsin-Madison

Charles Raison, M.D., is a professor at the School of Human Ecology at the University of Wisconsin-Madison and the Founding Director of the Center for Compassion Studies at the University of Arizona. His research examines the relationships between inflammation, stress, and the development of depression. His published work focuses on interventions for major depressive disorder and mental well-being, including whole-body hyperthermia, psilocybin-assisted therapy, and compassion-centered practices.

68 claims checked on air: 2 context 7 overstated 50 supported 9 unverified 7 flagged

What they said on air

3 citing their own research

0:01:32supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Depressed individuals show elevated levels of inflammatory markers like cytokines compared to healthy controls.

"if you measured inflammatory markers—so these are chemicals like cytokines that get kicked up when you get the flu, something like that—then when you looked at those sort of chemicals, they were actually elevated in depressed people." (said at 0:01:32)

Extensive meta-analytic evidence confirms that individuals with depression exhibit significantly elevated peripheral concentrations of inflammatory markers and cytokines compared to healthy controls. A comprehensive meta-analysis of 107 case-control studies encompassing 5,166 depressed individuals and 5,083 healthy controls demonstrated significantly higher circulating levels of pro-inflammatory cytokines and markers, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interleukin-12 (IL-12), interleukin-18 (IL-18), soluble IL-2 receptor (sIL-2R), and C-reactive protein (CRP). These elevations are also consistently observed in first-episode and antidepressant-naïve patients.

0:02:27supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

A very significant proportion of patients repeatedly administered interferon alpha for hepatitis C become clinically depressed.

"Turns out that if people do that to themselves on a repeated basis for something like curing hepatitis C, a very significant proportion of them become depressed. Many become like really clinically depressed, suicidal, hopeless, helpless." (said at 0:02:27)

Substantial clinical literature confirms that repeated administration of interferon-alpha for the treatment of chronic hepatitis C frequently induces clinically significant depression. A meta-analysis of 26 prospective observational studies found that the cumulative incidence of newly induced major depressive episodes in patients without baseline depression was approximately 25% to 28% across 24 to 48 weeks of antiviral therapy. Another systematic review found an overall incidence rate of major depressive episodes of 34.8% during interferon-alpha immunotherapy.

0:02:36supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

The vast majority of individuals who develop depression during interferon treatment recover completely within a couple of weeks of stopping the medication.

"The interesting thing is that the vast bulk of people recover pretty much completely within a couple of weeks of stopping it." (said at 0:02:36)

Clinical reviews evaluating interferon-induced neuropsychiatric side effects confirm that depressive symptoms commonly induced during interferon-alpha therapy generally resolve following treatment discontinuation or completion. While a small subset of patients may experience persistent symptoms or require pharmacological management, the depressive side effects typically resolve after stopping the medication.

0:03:06supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Severe infections requiring hospitalization or autoimmune conditions earlier in life significantly increase the risk of subsequently developing major depression and schizophrenia.

"if you have episodes of inflammation earlier in life—so for instance, if you have an autoimmune condition or if you have bad infections, the kind of infections that land you in the hospital—you're significantly more likely to subsequently develop significant major depression, but significant schizophrenia and other disorders, too" (said at 0:03:06)

Large nationwide prospective cohort studies confirm that prior autoimmune diseases and severe infections requiring hospitalization significantly increase the subsequent risk of developing both mood disorders (such as major depression) and schizophrenia. In Danish register-based cohorts of millions of individuals, a history of hospitalization for infection was associated with a 60% to 62% increase in the risk of subsequently developing schizophrenia (IRR 1.60, 95% CI 1.56–1.64) and mood disorders (IRR 1.62, 95% CI 1.60–1.64). Autoimmune disease was associated with a 29% increased risk of schizophrenia and a 45% increased risk of mood disorders, with risk increasing further when both factors co-occurred or following repeated hospitalizations.

0:05:11supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Medically healthy depressed individuals exhibit chronic elevations in core body temperature, particularly at night.

"We've known for many years that if you take medically healthy depressed people, they have chronic elevations in their body temperature, and it follows the same sort of diurnal pattern as you see in sickness. So you see more of this elevation at night." (said at 0:05:11)

Clinical studies demonstrate that individuals with major depressive disorder exhibit higher core body temperatures compared to non-depressed healthy controls, with the difference being particularly pronounced during nocturnal sleep. Research evaluating circadian temperature rhythms in depressed patients found elevated 24-hour mean and nighttime core body temperatures that significantly decrease and normalize following successful clinical treatment or recovery.

0:05:34supportedlowDr. Charles Raison on Depression, the Immune-Brain Interface

A UCLA study in the 1990s showed that depressed individuals have higher core body temperatures than non-depressed controls, and electroconvulsive therapy normalizes their core body temperature to control levels.

"there's some very interesting data, actually done up the road in Los Angeles at UCLA in the '90s, that if you measure core body temperature of people that are not depressed versus people that are, the depressed people's body temperature is higher. Then if you treat them—in this case, they used electroconvulsive therapy, which is, you know, very, very rapidly acting, powerful treatment—you treat the depressed people, you measure their body temperature again, bang, it goes right down to the level of control people." (said at 0:05:34)

A 1997 study conducted at the UCLA School of Medicine (Szuba et al.) monitored 24-hour core body temperature in 6 depressed patients before and after an electroconvulsive therapy (ECT) course compared to 6 matched healthy controls. Baseline core body temperature (mean 24-hour and asleep) was significantly higher in depressed patients than in controls. Following ECT, core body temperatures significantly decreased, matching the 24-hour temperature profile and levels of the non-depressed control group. While directly supporting the claim, certainty is rated low due to the very small sample size (n=6 per group).

0:06:10supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

During an acute-phase response, the liver decreases production of albumin, increases production of C-reactive protein (CRP), and reduces circulating levels of iron and zinc.

"one of the things that happens is something called an acute-phase reaction. So you get a change in the chemicals that your liver makes, right? So you get a downgrading of sort of housekeeping chemicals like albumin, and you get up-rising of things like CRP. And you tend to also do things like lose iron, lose zinc." (said at 0:06:10)

The speaker's statement accurately describes classic features of the systemic acute-phase response. During an acute-phase reaction (typically triggered by inflammatory cytokines such as IL-6, IL-1, and TNF-alpha), hepatic protein synthesis shifts: production of positive acute-phase reactants such as C-reactive protein (CRP) markedly increases, whereas synthesis of negative acute-phase proteins (such as albumin and transferrin) is downregulated. Concurrently, systemic micronutrient redistribution leads to significant reductions in circulating plasma concentrations of zinc and iron (the latter mediated via hepcidin induction and cellular sequestration into ferritin).

0:06:41overstatedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Iron supplementation during infection increases mortality, and children given iron in high-pathogen developing areas are significantly more likely to die of infection.

"And there's all sorts of data showing that, for instance, iron supplementation kills you if you're infected, or kids that are given iron in high-pathogen Third World areas are much more likely to die of infection." (said at 0:06:41)

The claim is an overstatement of findings from pediatric nutrition trials in malaria-endemic regions. The landmark 2006 Pemba trial in Zanzibar (over 24,000 children) found that routine daily iron and folic acid supplementation was associated with a 12% increased risk of the composite outcome of hospital admission or death (RR 1.12, 95% CI 1.02–1.23), primarily in iron-replete children in high-malaria settings lacking routine infection management. However, mortality alone was not statistically significantly increased (15% non-significant elevation, 95% CI -7% to 41%). Furthermore, comprehensive Cochrane systematic reviews and meta-analyses across dozens of randomized trials show that oral iron supplementation results in little to no significant difference in all-cause mortality (RR 1.15, 95% CI 0.76–1.74 for iron alone; RR 1.13, 95% CI 0.90–1.42 for iron plus folic acid). While safety concerns led public health guidelines to recommend targeting iron to iron-deficient individuals rather than universal untargeted supplementation in high-malaria zones without adequate medical care, the evidence does not show that iron supplementation 'kills you' or makes children 'much more likely to die of infection.'

0:08:38overstatedlowDr. Charles Raison on Depression, the Immune-Brain Interface

Prior to 10,000 years ago, hominids and humans predominantly died from physical trauma rather than epidemic crowd infections like smallpox, measles, and malaria.

"if you look at the things that killed hominids and human beings before about 10,000 years ago, they were largely not the infectious agents that killed us across history, right? So most people died of things like malaria and smallpox and measles—these horrible crowd infections—over the last 10,000 years, since the invention of agriculture. Before that, most people died from trauma." (said at 0:08:38)

The speaker correctly identifies that epidemic 'crowd infections' (such as smallpox and measles) largely arose and proliferated following the agricultural transition (~10,000 years ago) due to higher population densities and animal domestication. However, the assertion that pre-agricultural humans 'predominantly died from physical trauma' rather than illness or other infectious processes is overstated. In modern and prehistoric hunter-gatherer demographic and bioarchaeological analyses, non-epidemic infectious illnesses (such as acute respiratory infections, gastrointestinal diseases, and parasite- or pathogen-related sepsis) remain leading causes of mortality across the lifespan alongside trauma, predation, and violence, rather than trauma being the sole predominant cause.

0:11:30overstatedlowDr. Charles Raison on Depression, the Immune-Brain Interface

A pro-inflammatory MTHFR gene variant associated with depression risk is linked to increased survival against hepatitis B in sub-Saharan Africa.

"So we think about something like the MTHFR gene, right, that's involved in folate metabolism, right? So there's a form of it that seems to be a depression risk factor. So if you look at what it does immunologically, it is probably pro-inflammatory, and it's strongly associated with increased survival in sub-Saharan Africa because in sub-Saharan Africa, so many people initially die of hepatitis B, and the form of the gene that may be a risk factor for depression is actually protective against that illness." (said at 0:11:30)

Meta-analyses confirm a modest association between the MTHFR C677T polymorphism (T allele) and an increased risk of depression. Regarding hepatitis B, an observational comparative study in West Africa (Togo and Benin) found that the MTHFR 677T allele was associated with reduced odds of persistent chronic hepatitis B virus (HBV) infection, lower viral load, and higher anti-HBs antibody persistence. However, describing this as a strong association with increased overall survival against fatal hepatitis B in sub-Saharan Africa overstates the evidence, which comes from a single cross-sectional observational study evaluating markers of viral clearance rather than direct population survival data.

0:12:22supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

A study in Ghana found that a pro-inflammatory TNF gene haplotype (high TNF, low IL-10) was associated with earlier death in low-pathogen areas but protective against early-life mortality before age 40 in high-pathogen areas.

"It's a fascinating study out of the Netherlands, actually now probably 10 years ago, looking at Ghana... As you'd predict, in parts of the country where you are protected—so, you know, clean water, not going to die from infection—if you have the high-TNF, low-IL-10, sort of the pro-inflammatory haplotype, in the parts of the country with low pathogen, you die sooner. But in high-pathogen areas, they're protective, and the protection all occurs in the early part of the lifespan, up to the age of 40" (said at 0:12:22)

A 2009 study conducted by researchers from the Netherlands (Leiden University Medical Center) in the Upper-East region of Ghana (May et al., PLoS ONE) investigated genetic variation at the IL-10 locus influencing innate immune responses. They found that an IL-10 haplotype associated with a pro-inflammatory innate immune response (low IL-10 and high TNF-alpha) provided a survival advantage in high-pathogen environments (individuals using surface water from wells/rivers) but conferred a survival disadvantage in lower-pathogen environments (individuals with access to cleaner borehole water; interaction p = 0.013). This pro-inflammatory haplotype was significantly enriched in older age groups due to selective survival against fatal infectious diseases during early life.

0:14:55supportedlowDr. Charles Raison on Depression, the Immune-Brain Interface

In the Tsimané population of Bolivia, depression is strongly correlated with increased inflammation, and depressed individuals demonstrate enhanced immune responses to local pathogens.

"And so these folks—they're anthropologists at the University of New Mexico—actually went down to this group called the Tsimané... Depression was powerfully correlated with increased inflammation. And interestingly, when they did functional assays, the depressed people showed better immune responses to some of the pathogens, some of the types of things that would be pathogens in their world" (said at 0:14:55)

A 2015 study conducted among the Tsimané of Bolivia by anthropologists from the University of New Mexico and collaborating institutions investigated the relationship between depressive symptoms and immune function in an older adult sample (n = 649). The researchers found that depressive symptoms were significantly associated with elevated baseline inflammatory biomarkers (including TNF-alpha, IL-1beta, IL-6, and CRP) as well as heightened pro-inflammatory cytokine responses following ex vivo antigen stimulation.

0:17:29supportedlowDr. Charles Raison on Depression, the Immune-Brain Interface

A study by Capuron and Miller showed that the link between higher body mass index and cognitive-behavioral disturbance is mediated by increased inflammation.

"The best paper I know of was done by Lucile Capuron and Andy Miller—Lucile's in Bordeaux, Andy's at Emory—where they looked at cognitive behavioral disturbance, body mass index, and inflammation, and showed that the link between sort of obesity and these behavioral cognitive problems were mediated by the increased inflammation, right?" (said at 0:17:29)

A collaborative study by Lucile Capuron and Andrew H. Miller (2008) evaluated the relationship between metabolic syndrome (which includes abdominal adiposity/obesity), systemic inflammation (measured by IL-6 and CRP), and depressive symptom dimensions (affective-cognitive, mood, and neurovegetative symptoms) in 323 male twins from the Vietnam Era Twin Registry. The authors found that depressive symptoms were significantly associated with metabolic syndrome and that adjusting for systemic inflammatory status partially accounted for this relationship, identifying inflammation as an underlying mediator. Because this evidence comes from a cross-sectional observational design, certainty is rated as low.

0:18:14supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

Studies of patients undergoing gastric bypass surgery for weight loss demonstrate marked improvements in mood, depressive symptoms, and quality of life.

"The only data I know of from that are people that have had these gastric bypass surgeries for weight loss. And there's some data showing that, you know, they've administered, you know, kind of quality of life, well-being, mood stuff, people's moods will get much better." (said at 0:18:14)

Evidence from clinical trials and meta-analyses confirms that weight-loss interventions, including metabolic and bariatric surgical procedures, lead to significant improvements in mood, depressive symptoms, functional health status, and overall quality of life. A meta-analysis of randomized controlled trials evaluating weight-reducing treatments (surgical and pharmacological) found that clinically meaningful weight reduction was associated with a significantly reduced risk of major depression (MH-OR 0.45, 95% CI [0.21, 0.94]) and overall depression (MH-OR 0.72, 95% CI [0.54, 0.97]), alongside substantial improvements on validated mental and physical quality-of-life scales (such as the SF-36 Mental component and IWQOL-Lite).

0:20:01supportedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

Research by Jonathan Kipnis demonstrated that immune cells access the brain and meninges via functional lymphatic pathways connecting the immune system to the central nervous system.

"Cells get into the brain, as a matter of fact. This is the work of Jonathan Kipnis, fascinating." (said at 0:20:01)

Landmark research led by Jonathan Kipnis and colleagues identified functional lymphatic vessels in the dural meninges lining the sinuses of the central nervous system. These vessels express typical lymphatic endothelial markers, carry cerebrospinal fluid and immune cells, and connect directly to deep cervical lymph nodes, demonstrating a direct physical and functional route connecting CNS immune surveillance with the systemic immune system. Because the foundational discovery and mechanistic characterization were established primarily in animal models and preclinical tissue preparations, the certainty of evidence is graded as very low.

0:20:21needs contextmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Studies by Hugo Critchley's group showed that administering typhoid vaccine to healthy individuals induces acute dysphoria, increased feelings of social isolation, and changes in depressive brain circuitry.

"the folks in London, Hugo Critchley's group, they tended to use typhoid, and they showed it, right? You know, you give normal folks a shot of typhoid, which activates a sort of acute, mild—it's not, you know, feels like a sledgehammer, right? I mean, this is more like a ping. But you do that, and yeah, people report feeling more socially isolated, they feel more dysphoric, and you see changes in their brain that sort of speak to depressive brain functioning." (said at 0:20:21)

Hugo Critchley's group (Harrison et al., 2009) demonstrated in double-blind, randomized crossover trials that administering typhoid vaccination to healthy volunteers induces mild systemic inflammation (elevated IL-6), acute mood reduction/dysphoria, and altered activity and connectivity in brain regions implicated in depression (specifically the subgenual anterior cingulate cortex and mesolimbic circuits). However, the specific demonstration of acute inflammation increasing feelings of social disconnection and loneliness was established using endotoxin challenge models (e.g., Eisenberger et al., 2010), rather than Critchley's typhoid fMRI studies.

0:21:10supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

LPS endotoxin administration at UCLA induced depressive and dysphoric symptoms particularly in women compared to men.

"And the folks in UCLA used the LPS endotoxin, sort of saw the same thing, especially in women, not so much in men." (said at 0:21:10)

Researchers at UCLA (Moieni et al., 2015; Eisenberger et al., 2009) conducted double-blind, placebo-controlled randomized trials administering low-dose lipopolysaccharide (LPS) endotoxin to healthy male and female volunteers. They found that endotoxin induced significantly greater increases in self-reported depressed mood and feelings of social disconnection in female participants compared to male participants.

0:21:33unverifiedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

A German study found that administering endotoxin to severely depressed inpatients produced a strong antidepressant response.

"This was done years ago in Germany, where they actually took people that were catastrophically—it's a small study, but they took people that had been inpatient, catastrophically depressed, and they shot them up with endotoxin, and it produced a powerful antidepressant response." (said at 0:21:33)

No published record matching the claim that a German study administered endotoxin to severely depressed inpatients and produced a strong antidepressant response was located; this does not prove the claim false. In published biomedical literature, endotoxin (lipopolysaccharide) administration in humans is standardly used as an experimental model to induce transient systemic inflammation and depressive symptoms (sickness behavior), rather than as a therapeutic antidepressant intervention.

0:22:00supportedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

Raz Yirmiya's rodent study demonstrated that a 20-day stressor induces microglial apoptosis and depressive behavior; blocking inflammation before stress is protective, but stimulating inflammation after stress produces an antidepressant response.

"there's a relevant animal study from Raz Yirmiya in Israel, where they took mice—pretty sure mice, not rats—and subjected them to this 20-day horrible stressor, and they showed that the stressor crazily activates inflammation, leads to apoptosis, death of microglial cells in the brain, and, you know, huge anxious, depressive behavior afterwards, right? So what was interesting was they showed that if you block the inflammation right before the start of the stressors—so as it starts, you block it—you can prevent the apoptosis, you can prevent the downstream behavioral effects. It's protective, fine. If you do nothing here, and you let the little rodents go through the horrible stressor and you block inflammation afterwards, they do worse. If you stimulate inflammation, they get an antidepressant response." (said at 0:22:00)

The speaker accurately describes a 2014 rodent study from Raz Yirmiya's laboratory (Kreisel et al., Molecular Psychiatry). The researchers demonstrated that chronic unpredictable stress in mice caused an initial transient microglial activation followed by microglial apoptosis, loss of hippocampal microglia, and depressive-like behaviors. Inhibiting initial microglial activation with minocycline or interleukin-1 receptor antagonist prevented microglial decline and depressive-like behaviors. Conversely, once microglial decline had occurred after chronic stress, stimulating microglia with low-dose endotoxin (LPS) or colony-stimulating factors (M-CSF/GM-CSF) produced antidepressant-like behavioral rescue, whereas post-stress microglial inhibition with minocycline failed to provide benefit. Because the findings are restricted to animal models, the certainty of evidence for clinical depression in humans remains very low.

0:23:03unverifiedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

Pro-inflammatory cytokines such as TNF-alpha, IL-1 beta, and IL-6 exert neurotrophic effects in the brain at low physiological concentrations.

"these cytokines, these classic inflammatory molecules like TNF, tumor necrosis factor alpha, IL-1 beta, IL-6, at lower levels in the brain, they actually have neurotrophic effects." (said at 0:23:03)

No published record matching the claim that pro-inflammatory cytokines such as TNF-alpha, IL-1 beta, and IL-6 exert neurotrophic effects in the brain at low physiological concentrations was located; this does not prove the claim false.

0:23:29supportedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

TNF knockout mice demonstrate severe cognitive and spatial navigation deficits.

"if they've generated TNF knockout mice, they can't find their way out of a bag. They're dumb as dirt, right?" (said at 0:23:29)

Preclinical rodent studies consistently show that basal physiological levels of tumor necrosis factor-alpha (TNF-α) are required for normal synaptic plasticity, neurogenesis, and cognitive function. Mice with genetic deletion of TNF (TNF-/- knockouts) exhibit significant impairments in spatial navigation, spatial memory retention, and learning performance in standardized behavioral tests such as the Barnes maze, novel object recognition, and Y-maze compared to wild-type controls. While the colloquial characterization is hyperbolic, the factual premise that TNF knockout mice exhibit cognitive and spatial learning deficits is supported by animal evidence.

0:26:09supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

Andy Miller's studies showed that depressed patients with elevated inflammation exhibit distinct brain functional connectivity and different responses to immune agents compared to depressed patients with low inflammation.

"This is the work of my mentor Andy Miller in the last five or seven years. They've just been world leaders showing that if you take regular old depressed people—you got like 250 of them and did this amazing series of studies—people that have, there's not a cutoff, but people that have higher levels of inflammation who are depressed have different functional connectivity in their brains than people that have lower levels. And we showed, Andy and I showed years earlier, that they also have very different responses to immune agents than people that have lower levels of inflammation." (said at 0:26:09)

The claim is supported by published clinical and neuroimaging studies led by Andrew H. Miller, Charles L. Raison, and colleagues. In a resting-state fMRI study of depressed patients, higher levels of plasma C-reactive protein (CRP), a marker of inflammation, were significantly associated with reduced resting-state functional connectivity across a distributed neural network centered in the ventromedial prefrontal cortex (PMID 31078690). Furthermore, a randomized controlled trial of the anti-TNF immune agent infliximab in treatment-resistant depression showed a significant interaction based on baseline CRP: depressed patients with high baseline inflammation (hs-CRP > 5 mg/L) showed clinical improvement with infliximab compared to placebo, whereas those with lower baseline inflammation did not benefit (PMID 22945416).

0:30:10supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Food intake elevates core body temperature via diet-induced thermogenesis.

"The other thing is, you know, when you eat, it kind of gives you a fever. Think about diet-induced thermogenesis. So every time you eat, your body temperature elevates." (said at 0:30:10)

Diet-induced thermogenesis (the thermic effect of food) is the obligatory and facultative increase in metabolic rate and heat production following food ingestion. Physiological studies confirm that meal consumption increases postprandial heat production, mean body temperature, and core temperature in humans, though the magnitude is a modest physiological rise rather than a clinical fever.

0:31:03supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

A 24-hour fast in 19 healthy volunteers suppressed gene expression of the NLRP3 inflammasome, which reversed upon refeeding.

"There was a study in 19 normal volunteers, and they looked at the effect of a 24-hour fast on something called the NLRP3 inflammasome... So you fast, and that the expression, the gene expression for that complex just goes down, down, down, down, down. Then they let the people eat again, goes up, up, up, up, up." (said at 0:31:03)

A clinical study published in The Journal of Clinical Investigation evaluated 19 healthy volunteers who underwent a 24-hour fast followed by a fixed-calorie meal. The researchers found that NLRP3 inflammasome activation was significantly blunted during the 24-hour fast and reversed upon refeeding.

0:31:28supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Eating transiently increases intestinal permeability ('leaky gut').

"And if they look at that, it's sort of leaky gut, and you find that eating sort of opens the gut up to leakiness too" (said at 0:31:28)

Published human clinical studies and experimental models confirm that food and macronutrient ingestion (particularly high-fat meals, lipids, and refined sugars) transiently increases markers of intestinal permeability (such as circulating zonulin) and leads to postprandial translocation of bacterial products like endotoxin/lipopolysaccharide (postprandial metabolic endotoxemia) during the acute digestive phase.

0:34:05unverifiedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

Hot yoga elevates core body temperature to 38.5 degrees Celsius as measured by rectal probe.

"she especially is interested in and has a grant to study hot yoga and convinced people to wear a rectal probe while they're doing hot yoga. Hot yoga, which also, you know, makes people sweat like pigs, elevates core body temperature to, interestingly, oh, the exactly the same place." (said at 0:34:05)

No published record matching the specific claim that hot yoga elevates core body temperature to 38.5 °C as measured by a rectal probe was located; this does not prove the claim false. While published research has evaluated physiological responses and depression outcomes associated with heated yoga, published data demonstrating this specific temperature endpoint using rectal thermometry were not identified.

0:35:28overstatedlowDr. Charles Raison on Depression, the Immune-Brain Interface

Hot baths improve autistic symptoms in children.

"And there's some interesting data on hot baths improving autistic symptoms, right? And there's people at Kids in New York, right?" (said at 0:35:28)

The idea that hot baths improve autism spectrum disorder (ASD) symptoms stems from anecdotal and pilot observations exploring whether artificial hyperthermia could mimic the purported "fever effect" in autism. However, evidence demonstrating that hot baths reliably improve autistic symptoms is lacking. Retrospective surveys (such as the Simons Simplex Collection) found parent-reported behavioral improvements during natural fevers in only about 17% of children. Furthermore, prospective studies demonstrate that fever typically worsens emotional, social, and behavioral symptoms in most children with ASD, with consistent behavioral improvements documented in only a very small minority (e.g., ~2%).

0:38:54supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

Salvinorin A acts as a kappa-opioid receptor agonist.

"something called salvinorin A— ... is a kappa agonist, agonist, and there's also a significant interest at lower doses as an antidepressant, right?" (said at 0:38:54)

Salvinorin A, the principal active neoclerodane diterpenoid from Salvia divinorum, is well established in pharmacological literature as a potent and highly selective kappa-opioid receptor (KOR) agonist.

0:40:20unverifiedlowDr. Charles Raison on Depression, the Immune-Brain Interface

Elevated interleukin-6 (IL-6) levels are associated with increased risk of heart attacks, stroke, cancer, and hippocampal shrinkage.

"There's all sorts of evidence that if it's elevated, if you're a Western person hanging around, if I measure your IL-6 and if it's bad, you're going to get heart attacks, you're going to get strokes, you're going to get cancer, you're going to get, you know It's a bad deal to have your IL-6 high, it's going to shrink your hippocampus." (said at 0:40:20)

No published record matching the claim that elevated interleukin-6 levels cause or are associated with heart attacks, stroke, cancer, and hippocampal shrinkage was located; this does not prove the claim false.

0:40:45supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

Interleukin-6 (IL-6) stimulates the production of interleukin-10 (IL-10), providing anti-inflammatory signaling.

"it faces two directions because it also has anti-inflammatory effects, right, it activates IL-10" (said at 0:40:45)

The claim is supported by experimental human trials and established immunology literature. In a controlled human trial, recombinant human IL-6 infusion directly increased circulating levels of anti-inflammatory mediators, including interleukin-10 (IL-10) and interleukin-1 receptor antagonist (IL-1ra), while suppressing classic pro-inflammatory cytokines such as TNF-alpha.

0:40:53supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

Moderate exercise robustly increases IL-6 without raising systemic IL-1 or TNF levels.

"What exercise seems to do is it activates IL-6 like crazy, but it doesn't activate IL-1 or TNF in the blood. If you really, really exercise, like a maniac, yeah, you can get slight increases. If you look at sort of maybe less, you know, like horrible, you know, killer exercise, you see this big increase in IL-6. If you pull out people's blood cells and stimulate them, you actually see reduced release of TNF and IL-1" (said at 0:40:53)

Exercise stimulates the release of interleukin-6 (IL-6) from contracting skeletal muscle fibers without triggering classical pro-inflammatory cascade cytokines such as tumor necrosis factor-alpha (TNF-α) or IL-1 in the blood. In clinical studies of moderate concentric exercise, plasma IL-6 increases substantially while circulating IL-1α, IL-1β, and TNF-α remain undetectable or unchanged. In contrast, very prolonged or extreme strenuous exercise (such as a marathon) can cause minor elevations in TNF-α and IL-1β. Furthermore, the exercise-induced rise in IL-6 stimulates anti-inflammatory factors like IL-10 and IL-1 receptor antagonist (IL-1ra), inhibiting systemic TNF-α and IL-1 production and signaling.

0:41:47supportedlowtheir own paperDr. Charles Raison on Depression, the Immune-Brain Interface

In a Swiss pilot study of whole-body hyperthermia for depression, depression scores were reduced by half five days post-treatment.

"We did a first small open sort of clinical study in in Switzerland with these colleagues of mine found an old hyperthermia machine in the basement... and we started just sticking people in it and we saw this powerful antidepressant response that We only looked at people five days later, but clearly five days later their scores were generally cut in half, right?" (said at 0:41:47)

The speaker accurately describes an initial open-label pilot study conducted in Switzerland by their research group, in which a single session of whole-body hyperthermia (WBH) was evaluated in patients with major depressive disorder. In that preliminary trial (later reported in the literature and referenced in subsequent randomized trials), depressive symptoms assessed 5 days post-treatment dropped by approximately half from baseline. Because this was a small, uncontrolled open-label pilot, the certainty of evidence from the pilot alone is low, though its findings prompted subsequent randomized sham-controlled trials demonstrating significant antidepressant effects.

0:42:57supportedhightheir own paperDr. Charles Raison on Depression, the Immune-Brain Interface

Over 70% of subjects in the sham whole-body hyperthermia control group believed they received the real treatment.

"And so we put people in the box, we turned on the fake lights, we turned on the heating coils down there and the fan, and 70 percent, more than 70 percent of the people that got the fake treatment thought they got the real treatment." (said at 0:42:57)

In a randomized, double-blind, sham-controlled clinical trial investigating whole-body hyperthermia (WBH) for major depressive disorder (Janssen et al., JAMA Psychiatry 2016), the sham control procedure was designed to mimic all aspects of the intervention without the intense heat (using heating lights, coils, and fans). Blinding success was directly assessed: immediately following the intervention, 10 of 14 participants (71.4%) randomized to the sham control group believed they had received the active WBH treatment.

0:43:43supportedmoderatetheir own paperDr. Charles Raison on Depression, the Immune-Brain Interface

The magnitude of acute IL-6 elevation from whole-body hyperthermia strongly correlated with antidepressant response one week later.

"The the people who got the real heat, their IL-6 shoots up... Now, what's interesting is the higher your IL-6 went up, if you look at the whole population, the higher your IL-6 went up, the more undepressed you were a week later, and it was a pretty strong correlation." (said at 0:43:43)

In a randomized, sham-controlled trial evaluating whole-body hyperthermia (WBH) for major depressive disorder, active WBH produced a sharp, acute increase in plasma interleukin-6 (IL-6) immediately post-treatment compared to sham. Across the study sample, this post-treatment increase in IL-6 (and activation of classical IL-6 signaling) was significantly associated with greater reductions in Hamilton Depression Rating Scale (HDRS) depression scores during follow-up.

0:44:57unverifiedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

Whole-body hyperthermia induced an increase in neopterin that strongly correlated with IL-6 elevation.

"Neopterin is a chemical that's really only made by activated immune cells, by monocytes, these these innate immune pro-inflammatory cells. So we measured neopterin. Neopterin also went up and it correlated very strongly with the IL-6." (said at 0:44:57)

No published record matching the claim that whole-body hyperthermia induced an increase in neopterin that strongly correlated with interleukin-6 (IL-6) elevation was located; this does not prove the claim false. While published randomized trials examining whole-body hyperthermia in major depressive disorder demonstrate acute post-treatment increases in circulating IL-6, published reports describing concurrent neopterin induction and its direct correlation with IL-6 following whole-body hyperthermia are not available in the peer-reviewed medical literature.

0:45:36supportedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

Severe heat shock in rodents induces massive muscle-derived IL-6 release into circulation that suppresses TNF and IL-1.

"And there's animal data showing that if you induce heat shock, so if you really heat up a rodent, you get massive IL-6 production from the muscle cells that spills into the circulation and powerfully suppresses TNF and IL-1." (said at 0:45:36)

Animal research in mice confirms that severe hyperthermia (heat stroke/shock model up to a core temperature of 42.4°C) induces a rapid rise in muscle-derived interleukin-6 (IL-6) mRNA and protein that parallels elevated circulating IL-6 levels. This response is accompanied by an early transient suppression of muscle and circulating tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) expression. Because the supporting evidence comes exclusively from rodent models, the overall certainty for this specific animal-based finding is graded as very low.

0:45:57supportedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

Blocking IL-6 in exercising rodents abolishes the exercise-induced improvement in insulin sensitivity.

"And we know in the context of exercise that IL-6 plays a key role in exercise's ability to induce insulin sensitivity. So if you block IL-6 in a rodent that exercises, you block all the beneficial metabolic effects." (said at 0:45:57)

Rodent studies support the claim that blocking interleukin-6 (IL-6) abolishes the exercise-induced enhancement of insulin sensitivity. In mice injected with an IL-6 neutralizing antibody prior to acute exercise, the exercise-induced increases in skeletal muscle GLUT4 expression and insulin-stimulated glucose uptake were completely canceled. Similarly, in IL-6 knockout mice subjected to exercise training on a high-fat diet, the protective effects of voluntary running on insulin sensitivity and glucose tolerance were absent compared to wild-type controls. Because the available evidence consists solely of preclinical animal experiments, the GRADE certainty is very low.

0:46:09overstatedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Taking NSAIDs during exercise blunts exercise-induced muscle restructuring adaptations in humans.

"Now, there's also a study, interestingly, showing that if you look at the the beneficial effects of exercise on sort of muscle restructuring, this is in humans, if you exercise and take a non-steroidal anti-inflammatory, you get rid of all those good—" (said at 0:46:09)

Human randomized controlled trials show that high daily over-the-counter doses of NSAIDs (such as 1,200 mg/day ibuprofen) attenuate, but do not completely abolish, muscle hypertrophy and strength adaptations to resistance training in young adults. For example, an 8-week trial in young adults found quadriceps hypertrophy increased by 3.7% with daily ibuprofen compared to 7.5% with low-dose aspirin. However, claiming that NSAIDs eliminate all exercise adaptations is an exaggeration. Furthermore, the effect is dose- and population-dependent: lower or intermittent doses (such as 400 mg/day) do not impair hypertrophy in young adults, and in older adults, daily ibuprofen has actually been shown to enhance resistance training-induced muscle hypertrophy and strength gains.

0:49:06unverifiedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

Five days following whole-body hyperthermia, patients' 24-hour core body temperatures were lower than baseline.

"Right, and what we found, from five days after being in the box, your everybody's core body temperature was really lower over 24 hours. So the box didn't make people hotter, it made them cooler. What we were actually inducing was hypothermia." (said at 0:49:06)

No published record matching the claim that patients' 24-hour core body temperatures were lower than baseline five days following whole-body hyperthermia was located; this does not prove the claim false.

0:49:40unverifiedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

Higher baseline core body temperature before whole-body hyperthermia treatment correlates with a greater antidepressant response.

"And what we found was that the hotter you were before you got into the box, the better antidepressant response" (said at 0:49:40)

No published record matching the claim that higher baseline core body temperature before whole-body hyperthermia treatment correlates with a greater antidepressant response was located; this does not prove the claim false. While randomized clinical trials have established that whole-body hyperthermia significantly reduces depressive symptom severity compared to a sham procedure in major depressive disorder, the specific predictive correlation between baseline core body temperature and clinical response magnitude was not reported in available abstracts.

0:51:08supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Patients with schizophrenia exhibit impaired thermoregulation.

"They do. They've got horrible skin. They've got really, really crazy thermoregulatory challenges, right? So that I mean, when you see folks out—you know, it's a tragedy when you see them out on the street. One of the things you notice about schizophrenics: it could be hot and they're wearing three or four coats, right?" (said at 0:51:08)

Published medical literature supports the claim that individuals with schizophrenia exhibit impaired thermoregulation. People diagnosed with schizophrenia have marked vulnerabilities to thermal stress resulting from an interplay of intrinsic physiological abnormalities in central and autonomic temperature regulation, antipsychotic medication effects (which can interfere with sweating and hypothalamic temperature setpoints), and altered behavioral thermoregulatory responses (such as inappropriate clothing choices or impaired environmental sensing). Epidemiological and clinical reviews highlight that these thermoregulatory disruptions significantly elevate morbidity and mortality risks during extreme heat events.

0:52:54supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

Interferon-alpha treatment activates indoleamine 2,3-dioxygenase (IDO), shifting tryptophan metabolism away from serotonin and into kynurenine.

"So Michael Maes and Lucile Capuron and a number of people in the early 2000s began to show that chronic inflammation activated an enzyme—indoleamine 2,3-dioxygenase, right? And this is an enzyme that basically, as you said, takes tryptophan and shunts it away from serotonin into kynurenine." (said at 0:52:54)

Extensive clinical and translational research demonstrates that immune activation and cytokine therapy (such as interferon-alpha) induce indoleamine 2,3-dioxygenase (IDO). IDO metabolizes tryptophan along the kynurenine pathway, reducing tryptophan availability for serotonin synthesis and significantly increasing kynurenine levels and the kynurenine-to-tryptophan ratio.

0:53:43supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Interferon-alpha treatment causes a massive increase in quinolinic acid in human cerebrospinal fluid, which correlates strongly with depression.

"We got spinal fluid and showed that indeed—and this is really interesting—that the interferon definitely jacks up kynurenine. Kynurenine levels in the in the blood and the spinal fluid are very, very similar, so we think it's getting across. But you see a massive increase in quinolinic acid and kynurenic acid... Quinolinic acid skyrocketed under interferon treatment. That's what associated with depression powerfully." (said at 0:53:43)

A clinical study by Raison et al. (2010) examined CSF concentrations of kynurenine metabolites in hepatitis C patients treated with interferon-alpha (IFN-alpha). The authors found that IFN-alpha treatment significantly elevated CSF kynurenine, which led to marked increases in CSF quinolinic acid (QUIN) and kynurenic acid (KA). Furthermore, increases in CSF QUIN were significantly correlated with increased depressive symptoms assessed by the Montgomery-Asberg Depression Rating Scale.

0:54:14supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Under chronic inflammation from interferon-alpha, tryptophan levels decline in peripheral blood but remain maintained in human cerebrospinal fluid.

"Now, on the other hand, we actually measured tryptophan in the blood and the spinal fluid around the brain, and there was no effect. The tryptophan falls in the periphery, but it's maintained in the brain." (said at 0:54:14)

In a controlled study of hepatitis C patients receiving chronic treatment with interferon-alpha (IFN-alpha, ~12 weeks) compared to untreated controls, IFN-alpha administration caused a significant reduction in peripheral blood tryptophan levels without altering tryptophan concentrations in the cerebrospinal fluid (CSF).

0:54:40supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

Kynurenic acid acts as an NMDA receptor antagonist, whereas quinolinic acid acts as an NMDA receptor agonist with neurotoxic properties.

"setting aside kynurenic acid, which is interesting, it's an NMDA antagonist; quinolinic acid is an NMDA agonist. It causes neurotoxic effects." (said at 0:54:40)

The published literature firmly establishes the distinct pharmacological roles of these two tryptophan metabolites along the kynurenine pathway: kynurenic acid functions as an endogenous N-methyl-D-aspartate (NMDA) receptor antagonist (conferring neuroprotective properties), whereas quinolinic acid acts as an NMDA receptor agonist whose excessive receptor activation and downstream oxidative stress mediate excitotoxic and neurotoxic damage.

1:04:08supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Historically across human evolution, approximately 50% of people born died by age 15 from infection.

"We don't want to go back to the times when 50% of everybody born was dead by 15 from infection" (said at 1:04:08)

Cross-cultural and anthropological analyses of mortality across hunter-gatherer, traditional, and historical human populations demonstrate that approximately 40% to 50% of individuals died before reaching adulthood (age 15). Demographic reconstructions show that the vast majority of these pre-reproductive deaths were caused by infectious diseases, particularly respiratory and gastrointestinal illnesses.

1:05:30supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Fasting exerts powerful anti-inflammatory and beneficial metabolic effects.

"Fasting has powerful anti-inflammatory effects. It has powerful beneficial metabolic effects." (said at 1:05:30)

Systematic reviews and meta-analyses of randomized controlled trials demonstrate that fasting regimens (including intermittent fasting and time-restricted eating) exert beneficial metabolic and anti-inflammatory effects in adults. Meta-analyses show significant improvements in glycemic control (reductions in fasting blood glucose, HbA1c, and insulin resistance measured by HOMA-IR), reductions in LDL cholesterol, and reductions in key inflammatory markers such as tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), and interleukin-6 (IL-6). While the direction of effect is well established, the clinical magnitude of these changes is generally modest to moderate and comparable to continuous energy restriction rather than uniquely extraordinary.

1:05:42supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Studies administering mood questionnaires to patients fasting for conditions like pain demonstrate that fasting has mood-elevating effects.

"there's a lot of literature looking at fasting for sort of related things like pain. And many studies have given mood questionnaires: fasting has powerful mood-elevating effects" (said at 1:05:42)

Clinical and systematic reviews of therapeutic fasting (often studied in patients fasting for chronic pain syndromes, rheumatic diseases, and metabolic conditions) confirm that administering validated mood questionnaires frequently reveals mood enhancement, heightened vigilance, and a subjective sense of well-being or euphoria. Reviews evaluating clinical observations and questionnaire-based assessments note that fasting typically produces early improvements in depressive symptoms, alertness, and mood states between days 2 and 7.

1:06:45needs contextmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

In Japanese Zen marathon practice (kaihōgyō), participants undergo a 7-year training protocol culminating in running over 50 miles per day for 100 straight days, with only 48 people completing it since the 1850s.

"They have this seven-year crazy, crazy, crazy running protocol training where, at the end of it, people run more than 50 miles a day for a hundred days straight. And many people die doing this. And because they have to run carrying all their books, and they run in these crazy wooden shoes, and only 48 people have successfully done it since the 1850s." (said at 1:06:45)

The core outline of the *kaihōgyō* practice is broadly accurate: the full *sennichi kaihōgyō* (1,000-day circumambulation) is carried out across seven years on Mount Hiei, culminating in year seven with 100 consecutive days covering roughly 84 km (~52 miles) per day (the Kyoto Great Circuit). Historical records document approximately 46 to 50 completions since the late 19th century (1885). However, the claim contains several inaccuracies: the practice belongs to Tendai Buddhism (headquartered at Enryaku-ji on Mount Hiei), not Zen Buddhism; practitioners traditionally wear handwoven straw sandals (*waraji*), not wooden shoes; and the practice is a walking/chanting pilgrimage to sacred sites rather than running while carrying all their books.

1:09:25supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

The human foot and its specialized anatomy for running evolved long before the evolution of the modern human brain.

"we know that the human foot evolved long before the human brain. People had modern feet before they had modern brains, and the human foot is remarkably evolved for running: the arch, there's a whole huge story on this." (said at 1:09:25)

Paleoanthropological and biomechanical evidence supports the claim that modern foot anatomy and specialized adaptations for bipedal locomotion and endurance running (such as a longitudinal plantar arch, enlarged heel bone, and shortened toes) evolved significantly earlier in the hominin lineage than modern human brain expansion. Adaptations supporting endurance running and bipedal mechanics emerged with the early genus Homo and preceding australopiths approximately 2 to 3 million years ago, whereas modern human brain size and cranial architecture did not emerge until hundreds of thousands of years later.

1:09:40overstatedhighDr. Charles Raison on Depression, the Immune-Brain Interface

The human brain accounts for 30% of total energy utilization in the human body.

"these huge brains, which take up 30% of all the energy utilization in our body" (said at 1:09:40)

The adult human brain accounts for approximately 20% of the body's total basal energy and oxygen consumption despite representing only about 2% of total body weight. Stating that the human brain accounts for 30% of total body energy utilization overstates this established physiological proportion.

1:09:58unverifiedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

Quadrupedal mammals can only cool down by panting and are unable to gallop and pant simultaneously.

"all other animals, especially four-legged animals, can only cool off by panting, and they can't gallop and pant at the same time. So as long as you can keep an animal just at the pace where they have to gallop every once in a while, they can't cool off" (said at 1:09:58)

No published record matching the claim that four-legged animals can only cool off by panting and cannot pant while galloping was located; this does not prove the claim false.

1:15:17supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

Studies by Roland Griffiths and Stephen Ross showed that a single administration of psilocybin produced antidepressant and anxiolytic responses lasting six months or longer in cancer patients.

"Roland and Steve Ross at NYU—Roland at Hopkins—showed that, you know, a single exposure to something like psilocybin, which is the psychedelic substance in magic mushrooms, you know, tends to induce these very unusual states of mind that often have a kind of mystical characteristic to them. And a single exposure in a couple of studies induced these powerful antidepressant responses that lasted for like six months or longer." (said at 1:15:17)

Two landmark 2016 randomized double-blind crossover trials conducted by Roland Griffiths at Johns Hopkins University and Stephen Ross at New York University demonstrated that a single high dose of psilocybin (administered alongside psychological support) produced rapid, substantial, and sustained reductions in anxiety and depression in cancer patients. In both trials, 60% to 80% of participants maintained clinically significant antidepressant and anxiolytic responses at 6- to 6.5-month follow-up assessments, with the intensity of the session-day mystical-type experience mediating clinical outcomes.

1:15:45supportedlowDr. Charles Raison on Depression, the Immune-Brain Interface

In a long-term follow-up of depressed and anxious cancer patients treated with psilocybin, most surviving participants remained in remission from depression two years later without needing antidepressants.

"I know for Steve, you know, that he's followed up with people—these are depressed, anxious people with cancer—that those that are still alive two years later, many of them, most of them, are still undepressed and not taking—" (said at 1:15:45)

In a long-term follow-up study led by Dr. Stephen Ross and colleagues (PMID: 31916890), researchers re-evaluated surviving participants from their original randomized crossover trial of psilocybin-assisted psychotherapy for cancer-related distress (PMID: 27909164). Among the surviving participants contacted at mean follow-up intervals of 3.2 and 4.5 years (n=15), approximately 60% to 80% continued to meet criteria for clinically significant antidepressant and anxiolytic responses, with sustained reductions in depression, anxiety, hopelessness, and demoralization. Because this was a small, open-label within-subjects follow-up study (n=15) following a crossover trial, evidence certainty is low, but the reported outcomes directly match the speaker's account.

1:16:42supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Studies on interferon show that inflammatory molecules preferentially alter brain activity in the dorsal anterior cingulate cortex and default mode/rumination regions.

"We know from the interferon studies that one of the places that inflammatory molecules most change in the brain is the rumination center and the anterior—dorsal anterior cingulate, right?" (said at 1:16:42)

Human neuroimaging and spectroscopy studies in patients receiving interferon-alpha (IFN-alpha) treatment demonstrate that administration of this pro-inflammatory cytokine significantly alters neural activity and metabolic neurochemistry in the dorsal anterior cingulate cortex (dACC). Specifically, IFN-alpha administration increases dACC activation during task performance and elevates dACC glutamate concentrations, which correlate with error processing and depressive symptoms.

1:18:03supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Psychedelic therapies have demonstrated efficacy in smoking cessation.

"And not just that, but also these agents seem to have an anti-smoking effect. You help people quit smoking, you see the same thing that way." (said at 1:18:03)

Clinical trials of psychedelic-assisted therapy, particularly psilocybin combined with cognitive behavioral therapy (CBT), have demonstrated efficacy in promoting smoking cessation. An open-label pilot study (n=15) observed biochemically verified smoking abstinence rates of 67% at 12 months and 60% at long-term follow-up (mean 30 months). A subsequent pilot randomized clinical trial (n=82) comparing a single high dose of psilocybin plus CBT against nicotine replacement therapy (nicotine patch) plus CBT found significantly higher rates of 6-month biochemically verified prolonged abstinence in the psilocybin arm (40.5% vs. 10.0%, odds ratio 6.12). Systematic reviews corroborate that psychedelics show strong preliminary therapeutic potential for tobacco use disorder, though larger multicenter trials are ongoing.

1:18:44supportedlowDr. Charles Raison on Depression, the Immune-Brain Interface

Placebo responses in depression studies are more stable and longer-lasting than antidepressant responses upon discontinuation of treatment.

"Whereas initially, if you take away placebo, the people do pretty well. So placebo responses are more stable and more long-lasting than antidepressant responses, and that is a shockeroo and a downer for those of us in the field." (said at 1:18:44)

The claim accurately reflects findings in the placebo and antidepressant literature (notably summarized by Irving Kirsch and colleagues), which report that patients who respond to placebo show lower relapse rates and greater symptom stability following treatment cessation compared to patients whose antidepressants are discontinued. However, the evidence certainty is rated as low because these comparisons often rely on naturalistic follow-ups, narrative reviews, or secondary trial analyses where placebo responders represent a self-selected subgroup with milder baseline illness or spontaneous remission, rather than large head-to-head randomized trials directly testing post-discontinuation stability.

1:20:43supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Research by Richard Davidson and others shows that an eight-week meditation program induces measurable changes in brain function and activity in meditation novices.

"Richie Davidson, a colleague of mine, one of my sort of mentors at University of Wisconsin, has done studies showing that you can take people that are novices and get effects if you really give them like eight weeks of hardcore meditation." (said at 1:20:43)

Randomized controlled trials led by Richard Davidson and colleagues demonstrate that an 8-week mindfulness meditation intervention (such as Mindfulness-Based Stress Reduction, MBSR) induces measurable changes in brain function and neural activity among meditation-naïve participants. In a seminal 2003 trial, meditation novices completing an 8-week program exhibited significant increases in left-sided anterior brain activation on EEG compared to wait-list controls. Subsequent neuroimaging trials by the group in meditation-naïve adults have also demonstrated functional changes, including altered amygdala reactivity, increased functional connectivity between the amygdala and ventromedial prefrontal cortex, and altered resting-state functional connectivity between the default mode and executive control networks.

1:24:00unverifiedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

Research led by John Krystal at Yale showed that approximately 70% of depressed patients do significantly better short-term on an antidepressant than on placebo, while 25% do worse on an antidepressant than on placebo.

"John Krystal at Yale did this great study where they were able to—I won't bore you with the details, but what really happens is about 70% of people in the United States will do much better in terms of a short-term with an antidepressant than they will with a placebo. I mean, they really feel better. So there is a group of people that really do well with antidepressants... 25% of people that are depressed will do much worse with an antidepressant than they would with a sugar pill" (said at 1:24:00)

No published record matching the claim that research led by John Krystal showed approximately 70% of depressed patients do significantly better short-term on an antidepressant than on placebo while 25% do worse than on placebo was located; this does not prove the claim false.

1:28:28overstatedhighDr. Charles Raison on Depression, the Immune-Brain Interface

Studies demonstrate that among depressed patients who achieve full remission on antidepressants for two years, 60% to 80% relapse within one month if the medication is discontinued rapidly.

"you take people that have been in full remission taking an antidepressant for two years, you take it away, and 60-80% of them will relapse within a month, especially if you stop it quickly." (said at 1:28:28)

While randomized controlled trials confirm that discontinuing antidepressant therapy after long-term use significantly increases the risk of relapse compared to maintenance therapy, the claimed 60% to 80% relapse rate within a single month is substantially overstated. In the landmark ANTLER randomized trial, which evaluated primary care patients in remission after taking antidepressants for 2 years or longer, the cumulative relapse rate in the discontinuation group reached 56% over an entire 52-week (one-year) follow-up period, not within one month. Meta-analyses and discontinuation studies similarly show that while rapid discontinuation increases early relapse risk compared to slow tapering, relapse accumulates over months to years rather than affecting 60% to 80% of patients within four weeks.

1:33:41supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

The WILD 5 program, developed by Rakesh and Saundra Jain, is an intervention combining exercise, diet, sleep, social connectivity, and mindfulness.

"Rakesh and Saundra Jain, J-A-I-N. They have developed a program called the WILD 5, which is a fascinating, online-based resource that basically combines exercise, diet, sleep, social connectivity, and—what am I missing? ... And mindfulness." (said at 1:33:41)

The WILD 5 Wellness program (Wellness Interventions for Life's Demands), developed by Saundra Jain and Rakesh Jain, is a structured self-management wellness program that integrates five core lifestyle domains: exercise, nutrition (diet), sleep, social connectedness, and mindfulness.

1:36:08supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Sleep deprivation promotes systemic inflammation and weight gain.

"Yeah, inflammation, weight gain, oh, all of it." (said at 1:36:08)

Meta-analyses of human experimental and observational studies support that sleep deprivation/restriction increases systemic inflammatory markers and promotes weight gain. An updated meta-analysis of experimental sleep deprivation trials demonstrated that multiple nights of partial sleep restriction (~4.5 hours per night for 3 or more nights) significantly increased circulating levels of interleukin-6 (IL-6) and C-reactive protein (CRP). Similarly, meta-analyses of randomized controlled trials indicate that sleep restriction increases subjective hunger, leads to higher daily energy intake (+252.8 kcal/day), and results in modest short-term weight gain alongside impaired insulin sensitivity.

1:36:55supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

Circadian light exposure entrains diurnal cortisol rhythms and cytokine rhythms in humans.

"that's what entrains to a large degree cortisol rhythms, and probably cytokine rhythms do also, right?" (said at 1:36:55)

Extensive experimental and clinical evidence demonstrates that ocular light exposure acts as the primary environmental zeitgeber entraining the central master circadian pacemaker (the suprachiasmatic nucleus), which in turn drives the phase, amplitude, and diurnal rhythmicity of hypothalamic-pituitary-adrenal (HPA) axis activity and cortisol secretion in humans. Circadian entrainment of central and peripheral clocks subsequently coordinates rhythmic downstream physiological processes, including diurnal immune and cytokine oscillations.

1:41:49supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

Exposure to even a small amount of light, particularly blue light, disrupts nocturnal melatonin release.

"even a little bit of light absolutely screws up melatonin release, you know. Blue light mostly, I mean, that's where it's really smart to do this." (said at 1:41:49)

Human laboratory experiments demonstrate that nocturnal melatonin secretion is highly sensitive to light exposure, with peak sensitivity in the short-wavelength (blue) spectrum (~460–480 nm) mediated primarily by melanopsin-containing intrinsically photosensitive retinal ganglion cells (ipRGCs). Controlled fluence-response and spectral sensitivity studies show that even low-irradiance light and brief pulses of blue light significantly suppress circulating melatonin levels and shift circadian phase.

1:43:20supportedvery lowDr. Charles Raison on Depression, the Immune-Brain Interface

Thomas Wehr conducted a study at NIMH placing a treatment-resistant bipolar patient in 12 hours of darkness daily for about a year, resulting in remission of cycling.

"And there's a guy named Tom Wehr. He's been retired now, but he was sort of the king of the circadian stuff for many years at NIH, the National Institute of Mental Health. And he actually took—he did this great study where in particular he took this one just impossibly bipolar person, stuck him in the dark for 12 hours every day for a year or so, and just profoundly fixed the guy, right?" (said at 1:43:20)

Thomas A. Wehr and colleagues at the National Institute of Mental Health (NIMH) published a landmark case study in 1998 detailing the treatment of a patient with refractory, rapid-cycling bipolar disorder using extended bed rest in complete darkness (initially 14 hours per night, later tapered to 10 hours, averaging ~12 hours). The intervention stabilized the patient's sleep and stopped the rapid cycling between depression and mania over several years of follow-up. Because this evidence is derived from a single uncontrolled case report, the certainty of evidence for clinical efficacy across broader populations is very low.

1:45:42supportedmoderateDr. Charles Raison on Depression, the Immune-Brain Interface

Sleep deprivation can trigger manic episodes in individuals with bipolar disorder.

"So a great way to induce a manic episode is to just keep people awake. ... So there's wonderful data from the 1980s from the National Institute of Mental Health where they'd keep really very ill bipolar patients in psychiatric wards for years and study every episode. And always depressive, and but especially manic episodes, would be triggered by a night of sleep deprivation, right?" (said at 1:45:42)

Published literature directly supports the claim. Classic clinical research conducted at the National Institute of Mental Health (NIMH) by Thomas Wehr and colleagues in the 1980s studied patients with rapid-cycling bipolar disorder on inpatient units and demonstrated that experimental and spontaneous sleep loss frequently triggered switches into hypomanic or manic episodes. Wehr formulated the model that sleep reduction acts as a final common pathway through which diverse environmental, psychological, and pharmacological triggers precipitate mania.

1:46:26supportedlowDr. Charles Raison on Depression, the Immune-Brain Interface

A study conducted at Heathrow Airport found a significantly higher risk of passengers presenting with psychotic mania when traveling eastward from America compared to traveling westward from Asia.

"There's a beautiful study from Heathrow showing that there's a hugely increased risk of people showing up at Heathrow with a psychotic mania if they come from America to Heathrow than if they come from Asia to Heathrow." (said at 1:46:26)

A classic 1982 observational study of 186 psychiatric admissions from Heathrow Airport to the local psychiatric hospital found a significant relationship between travel direction and affective illness presentations. Depression was diagnosed significantly more frequently following east-to-west travel, whereas hypomania was inversely related, showing a significantly higher occurrence following west-to-east travel (such as flights arriving from America) compared to east-to-west travel (such as flights arriving from Asia).

1:46:33supportedhighDr. Charles Raison on Depression, the Immune-Brain Interface

Ellen Frank at the University of Pittsburgh developed chronotherapeutic approaches for bipolar disorder focusing on the regulation of regular daily sleep-wake and activity schedules.

"Ellen Frank was one of the originators of this, called chronotherapy, came out of the University of Pittsburgh, where they actually—as a therapeutic thing for bipolar, part of it was education about you always go to sleep at the same time, you get up at the same time, you'd be careful about air travel, right?" (said at 1:46:33)

Ellen Frank and colleagues at the University of Pittsburgh developed Interpersonal and Social Rhythm Therapy (IPSRT), a psychotherapeutic and chronotherapeutic approach designed to stabilize daily social and biological rhythms, including regular sleep-wake schedules, in patients with bipolar disorder. Randomized controlled trials have demonstrated that increasing social rhythm regularity reduces the likelihood of bipolar recurrence.

Fact-checked episodes

Publications